Related Experiment Video
Updated: Apr 12, 2026
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
A new strategy for metachronous primary lung cancer: stereotactic body radiation therapy with concurrent chemotherapy
Jumpei Takeshita1, Katsuhiro Masago2, Ryoji Kato2
1Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan jumpeinr2tfm3@fbri.org.
Background/Aim:
Patients with malignant lung cancer often develop a solitary pulmonary nodule after treatment of the initial cancer. In those cases, it is difficult to distinguish primary lung cancer (PLC) from lung metastasis. Therefore, both local therapy for a single lung lesions and systemic therapy for micrometastases are needed. This retrospective study aimed to evaluate the safety and tolerability of concurrent stereotactic body radiation therapy (SBRT) and chemotherapy in patients with metachronous PLC.
Patients And Methods:
We reviewed the records of 10 patients with metachronous PLC treated with SBRT and concurrent chemotherapy with curative intent from 2007 to 2013. The delivered radiation dose was 48 Gy in four fractions.
Results:
All patients received SBRT with concurrent chemotherapy on schedule. Complete response rate was 90%. Safety profile of this treatment was compatible with that of traditional chemoradiotherapy.
Conclusion:
Our study showed good feasibility and safety for SBRT with concurrent chemoradiotherapy.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017